Syneos Health

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Syneos Health reports mixed Q4 results, focuses on growth strategies

Syneos Health's Q4 performance showed mixed results with revenue decline but growth on a constant currency basis. The company is focused on enhancing its operating model, customer engagement, and winning new business opportunities.
Challenges include evaluating spending by large pharma customers and the need for cost structure realignment. However, opportunities lie in engaging with analysts, driving cost savings, and expecting larger pharma awards in 2023.
Overall, Syneos Health remains confident in its strategy, investments, and ability to drive growth in Clinical. The company is navigating challenges while leveraging strengths in customer relationships and value-based pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

MORRISVILLE, N.C., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today reported financial results for the three and nine months ended September 30, 2022.

Syneos Health Reports Third Quarter 2022 Results

Brings Together the Industry's Most Comprehensive Suite of Modular Patient Services, Optimizing Patient Experience from Prescription to Adherence Brings Together the Industry's Most Comprehensive Suite of Modular Patient Services, Optimizing Patient Experience from Prescription to Adherence

Syneos Health Adds HUB Patient Suite to Deployment Solutions Business

SAN FRANCISCO--(BUSINESS WIRE)--Phil Inc., a patient access platform company that revolutionizes life science product commercialization with technology to improve patient prescription access, today announced an exclusive partnership with Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization.

Phil, Inc. Forges Strategic Partnership with Syneos Health to Improve Patient Access to Prescriptions

MORRISVILLE, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2022 financial results on Friday, November 4, 2022, prior to its earnings call at 8:00 a.m. ET.

Syneos Health Schedules Third Quarter 2022 Earnings Call for Friday, November 4, 2022

MORRISVILLE, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of William E. Klitgaard to its Board of Directors. Mr. Klitgaard was previously a member of the Syneos Board from 2017 until May 2022, having resigned due to a personal matter. The Company also announced today that Todd M. Abbrecht is stepping down from its Board of Directors.

Syneos Health Appoints William E. Klitgaard Independent Director

MORRISVILLE, N.C., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has been awarded a Triangle Business Journal 2022 Leaders in Diversity Award for notable accomplishments in the field of Diversity, Equity & Inclusion (DE&I). The Company was recognized for its DE&I programs and strong focus on building a culture that values diversity of thought, experiences, perspectives and backgrounds.

Syneos Health Wins Triangle Business Journal 2022 Leaders in Diversity Award

Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for Clients Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for Clients

Syneos Health Expands Partnership with Datavant to Accelerate Delivery of New Therapies to Patients

Report Spotlights Significant Progress Toward Achieving Company's Environmental, Social and Governance Goals, Including Climate Pledge and DE&I Objectives Report Spotlights Significant Progress Toward Achieving Company's Environmental, Social and Governance Goals, Including Climate Pledge and DE&I Objectives

Syneos Health Releases Annual Sustainability Report

MORRISVILLE, N.C, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe and Chief Financial Officer Jason Meggs are scheduled to present at the 2022 Baird Global Healthcare Conference on September 13, 2022, at 2:00 p.m. ET.

Syneos Health to Present at the 2022 Baird Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)-- #AI--A leader in continuous remote patient monitoring and data analytics, physIQ today announced a strategic collaboration with InCarda Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases. Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, recommended physIQ's innovative monitoring solution to help advance InCarda's clinical

physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health to Accelerate Innovative Phase III Study in Patients with Atrial Fibrillation

Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.

Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View

Syneos Health, Inc. (NASDAQ:SYNH ) Q2 2022 Earnings Conference Call August 2, 2022 9:00 AM ET Company Representatives Michelle Keefe - Chief Executive Officer Jason Meggs - Chief Financial Officer Michael Brooks - Chief Operating Officer Ronnie Speight - Senior Vice President, Investor Relations Conference Call Participants Luke Sergott - Barclays Dave Windley - Jefferies Patrick Donnelly - Citi Christine Rains - William Blair Casey Woodring - JP Morgan Sandy Draper - Guggenheim Elizabeth Anderson - Evercore Eric Coldwell - Baird Ann Hynes - Mizuho Operator Good morning and welcome to the Syneos Health, Second Quarter 2022 Earnings Conference Call. At this time all participants are in listen-only mode.

Syneos Health, Inc. (SYNH) CEO Michelle Keefe on Q2 2022 Results - Earnings Call Transcript

Syneos Health (SYNH) delivered earnings and revenue surprises of 4.17% and 1.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Beats Q2 Earnings Estimates

MORRISVILLE, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today reported financial results for the three and six months ended June 30, 2022.

Syneos Health Reports Second Quarter 2022 Results

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth

MORRISVILLE, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2022 financial results on Tuesday, August 2, 2022, prior to its earnings call at 9:00 a.m. ET.

Syneos Health Schedules Second Quarter 2022 Earnings Call for Tuesday, August 2, 2022

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Syneos Health (SYNH) is a Top-Ranked Growth Stock: Should You Buy?

Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.

Here's Why Investors Should Retain Syneos Health (SYNH) For Now

MORRISVILLE, N.C., May 24, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences. Chief Executive Officer Michelle Keefe and Chief Financial Officer Jason Meggs are scheduled to present at the following conferences:

Syneos Health to Present at Upcoming Investor Conferences

Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

Syneos Health Inc's (NASDAQ: SYNH) Q1 revenue increased 10.5% on a reported basis and 11.7% on a constant currency (CC) basis to $1.34 billion, beating the consensus of $1.32 billion. Clinical Solutions revenue increased 8.4% (+9.6% CC) to $1.02 billion.

Syneos Health Shares Jump On Better Than Expected Q1 Earnings, FY22 Outlook

Syneos Health, Inc. (NASDAQ:SYNH ) Q1 2022 Earnings Conference Call April 29, 2022 8:00 AM ET Company Participants Ronnie Speight - SVP, IR Alistair Macdonald - CEO Michelle Keefe - CEO Jason Meggs - CFO Michael Brooks - Chief Operating Officer Conference Call Participants Eric Coldwell - Baird Casey Woodring - JP Morgan Christine Rains - William Blair Justin Bowers - Deutsche Bank David Windley - Jefferies Sandy Draper - Guggenheim Securities Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear.

Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q1 2022 Results - Earnings Call Transcript

Syneos Health (SYNH) delivered earnings and revenue surprises of 5.21% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Q1 Earnings and Revenues Top Estimates

Alistair Macdonald to Retire After 20 Years in Variety of Leadership Roles

News for Syneos Health Stock (SYNH)